JPWO2020246120A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020246120A5 JPWO2020246120A5 JP2021524680A JP2021524680A JPWO2020246120A5 JP WO2020246120 A5 JPWO2020246120 A5 JP WO2020246120A5 JP 2021524680 A JP2021524680 A JP 2021524680A JP 2021524680 A JP2021524680 A JP 2021524680A JP WO2020246120 A5 JPWO2020246120 A5 JP WO2020246120A5
- Authority
- JP
- Japan
- Prior art keywords
- orally disintegrating
- disintegrating tablet
- powder
- tablet
- acetaminophen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 88
- 239000006191 orally-disintegrating tablet Substances 0.000 claims description 59
- 229960005489 paracetamol Drugs 0.000 claims description 44
- 239000003826 tablet Substances 0.000 claims description 39
- 239000000843 powder Substances 0.000 claims description 36
- 239000002245 particle Substances 0.000 claims description 33
- 238000002156 mixing Methods 0.000 claims description 26
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 229920002678 cellulose Polymers 0.000 claims description 14
- 239000007884 disintegrant Substances 0.000 claims description 14
- 239000001913 cellulose Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 239000000796 flavoring agent Substances 0.000 claims description 10
- 210000000214 mouth Anatomy 0.000 claims description 9
- 235000003599 food sweetener Nutrition 0.000 claims description 7
- 239000003765 sweetening agent Substances 0.000 claims description 7
- 235000013355 food flavoring agent Nutrition 0.000 claims description 6
- 239000003205 fragrance Substances 0.000 claims description 5
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 4
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 229940041616 menthol Drugs 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 2
- 239000000120 Artificial Saliva Substances 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 235000005979 Citrus limon Nutrition 0.000 claims description 2
- 244000131522 Citrus pyriformis Species 0.000 claims description 2
- 240000000560 Citrus x paradisi Species 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 2
- 244000246386 Mentha pulegium Species 0.000 claims description 2
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 2
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 244000228451 Stevia rebaudiana Species 0.000 claims description 2
- 239000004376 Sucralose Substances 0.000 claims description 2
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 2
- 229960004998 acesulfame potassium Drugs 0.000 claims description 2
- 239000000619 acesulfame-K Substances 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 229940065115 grapefruit extract Drugs 0.000 claims description 2
- 235000001050 hortel pimenta Nutrition 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 2
- 235000019204 saccharin Nutrition 0.000 claims description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 2
- 229940081974 saccharin Drugs 0.000 claims description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 2
- 239000008109 sodium starch glycolate Substances 0.000 claims description 2
- 235000019408 sucralose Nutrition 0.000 claims description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 16
- 235000019658 bitter taste Nutrition 0.000 description 16
- 229940088679 drug related substance Drugs 0.000 description 16
- 235000010980 cellulose Nutrition 0.000 description 10
- 238000001000 micrograph Methods 0.000 description 6
- 238000009826 distribution Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000004513 sizing Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000010008 shearing Methods 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 238000003332 Raman imaging Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000019606 astringent taste Nutrition 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000003907 antipyretic analgesic agent Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000007561 laser diffraction method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019106806 | 2019-06-07 | ||
| JP2019106806 | 2019-06-07 | ||
| PCT/JP2020/014429 WO2020246120A1 (ja) | 2019-06-07 | 2020-03-30 | 口腔内崩壊錠及びその製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020246120A1 JPWO2020246120A1 (https=) | 2020-12-10 |
| JPWO2020246120A5 true JPWO2020246120A5 (https=) | 2022-05-19 |
| JP7360460B2 JP7360460B2 (ja) | 2023-10-12 |
Family
ID=73653120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524680A Active JP7360460B2 (ja) | 2019-06-07 | 2020-03-30 | 口腔内崩壊錠及びその製造方法 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP7360460B2 (https=) |
| WO (1) | WO2020246120A1 (https=) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3680627B2 (ja) * | 1999-04-27 | 2005-08-10 | 富士電機機器制御株式会社 | ノイズフィルタ |
| JP3389205B2 (ja) * | 1999-06-29 | 2003-03-24 | 武田薬品工業株式会社 | 口腔内速崩壊錠 |
| JP4719899B2 (ja) * | 2000-01-07 | 2011-07-06 | 大正製薬株式会社 | 口腔内速崩壊性錠剤 |
| CN1271997C (zh) * | 2004-02-27 | 2006-08-30 | 石药集团中奇制药技术（石家庄）有限公司 | 对乙酰氨基酚口腔崩解片及其制备方法 |
| JP3996626B2 (ja) * | 2004-06-22 | 2007-10-24 | 塩野義製薬株式会社 | 口腔内速崩壊錠 |
| JP5499599B2 (ja) * | 2008-10-01 | 2014-05-21 | 大正製薬株式会社 | アセトアミノフェン含有錠剤 |
| JP5575119B2 (ja) * | 2009-05-20 | 2014-08-20 | 大日本住友製薬株式会社 | 口腔内崩壊錠 |
| JP2011157348A (ja) * | 2010-01-05 | 2011-08-18 | Fuji Chem Ind Co Ltd | 崩壊性高強度球状粒子組成物 |
| EP2745848B1 (en) * | 2011-09-26 | 2023-04-12 | Nippon Soda Co., Ltd. | Orally disintegrating tablet containing hydroxyalkyl cellulose fine particles |
| IN2014DN07797A (https=) * | 2012-03-29 | 2015-05-15 | Daicel Corp | |
| JP6926404B2 (ja) * | 2015-06-12 | 2021-08-25 | ゼリア新薬工業株式会社 | 口腔内崩壊錠 |
| CN109069455B (zh) * | 2016-05-10 | 2020-10-09 | 日本脏器制药株式会社 | 对乙酰氨基酚制剂的制造方法 |
| US20190328674A1 (en) * | 2016-06-16 | 2019-10-31 | Towa Pharmaceutical Co., Ltd. | Orally disintegrating tablet |
| JP6832753B2 (ja) * | 2017-03-09 | 2021-02-24 | 旭化成株式会社 | セルロース複合体 |
-
2020
- 2020-03-30 WO PCT/JP2020/014429 patent/WO2020246120A1/ja not_active Ceased
- 2020-03-30 JP JP2021524680A patent/JP7360460B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5718231B2 (ja) | エリスリトールの打錠 | |
| KR101626873B1 (ko) | 구강붕해정제 | |
| JP5623275B2 (ja) | 直接打錠可能なデキストロース | |
| EP2007384B1 (en) | Orodispersible domperidone tablets | |
| JP5062872B2 (ja) | 不快な味を低減した口腔内崩壊錠剤 | |
| US4882161A (en) | Chewable, non-gritty calcium citrate tablet | |
| JPH10120554A (ja) | 無機制酸剤含有速分散性造粒物、その製造方法及び用時懸濁内服制酸剤 | |
| JP2003261439A (ja) | 口腔内崩壊製剤 | |
| JP2003146889A (ja) | 制酸・緩下用錠剤 | |
| JP5004236B2 (ja) | 口腔内崩壊錠 | |
| WO2011087705A2 (en) | Fine particle croscarmellose and uses thereof | |
| CN101401796A (zh) | 普拉克索口腔崩解片及其制备方法 | |
| JPWO2020246120A5 (https=) | ||
| JP2001322927A (ja) | 低置換度ヒドロキシプロピルセルロース含有固形製剤及びその製造方法 | |
| JP5799061B2 (ja) | トスフロキサシンおよびポリビニルピロリドンを含有する粒状固形製剤 | |
| JP2008044870A (ja) | 医薬組成物及びその製造方法 | |
| JP3698652B2 (ja) | 低置換度ヒドロキシプロピルセルロース含有固形製剤及びその製造方法 | |
| WO2011151018A2 (en) | Orodispersible tablets of erythritol and isomalt | |
| JP7360460B2 (ja) | 口腔内崩壊錠及びその製造方法 | |
| CN107921045B (zh) | 唑吡坦组合物及其制备方法 | |
| JP2001302510A (ja) | ステビア抽出物を配合したｈ２受容体拮抗剤含有製剤 | |
| CA2225674A1 (en) | Therapeutic effervescent compositions | |
| WO2020032159A1 (ja) | 粒状組成物及びその製造方法 | |
| JP2019218277A (ja) | 固形医薬組成物及びその製造方法 | |
| JP2019218278A (ja) | 医薬組成物 |